Comments must be submitted by September 27, 2021.
The Office of the U.S. Trade Representative (USTR) today released for publication in the Federal Register a notice and request for comments concerning the Section 301 investigation of China’s acts, policies, and practices related to technology transfer, intellectual property, and innovation.
Prior USTR notices excluded from additional customs duties certain medical care products that were intended to address the coronavirus (COVID-19) disease. The USTR in March 2021 extended certain product exclusions—that is, removed Section 301 customs duties from medical care products that address COVID-19—through September 30, 2021. Read TradeNewsFlash
According to today’s USTR notice [PDF 224] with the recent spread of the Delta variant of COVID-19, there are increasing numbers of medical cases in the United States. In light of these changing circumstances, including the ability of the United States to obtain certain products domestically or from other sources, the USTR is requesting public comments as to whether to extend particular exclusions for COVID-19 products for up to six months.
Source KPMG
Latest Posts in "China"
- China’s Tax Crackdown Disrupts Copper and Metals Trade, Slashing Invoice Quotas and Transactions
- China Reports Surge in Instant VAT Refunds for Departing Tourists After New Policy
- Policy Boost: Expanded Tax Rebate Scope for Pingtan’s “Second Line” Goods Announced
- China’s Invoice Crackdown Disrupts Copper, Aluminium, Silver Trading in Shanghai Markets
- China’s New Supply Chain Laws: Legal Risks and Compliance Challenges for Multinationals
